Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.
US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...
They came of age without fillers or selfies, now they’re approaching aesthetic interventions in their own unique way.
Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, ...
ARIANA Grande shot to fame aged 16 as an innocent-looking Nickelodeon star with bright red hair. But since then, the child actress-turned-pop star has undergone a full transformation – one ...
A Common Sense Media study conducted on body image and the media found that, between 1999 and 2006, hospitalization for ...
Novo Gains Fueled by Ozempic and Wegovy Fade | The drugmaker's shares have ... of CagriSema that would allow its two drug ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback